Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Swiss Garnier Life Sciences

    Swiss Garnier Life Sciences started its operations in the year 2004. Its manufacturing facilities is located in Una district of Himachal Pradesh

  • No Image
    Symbiosis Pharmaceuticals Pvt Ltd

    Symbiosis Pharmaceuticals Pvt Ltd was incorporated at Kala Amb, Himachal Pradesh, in the year 2003. The company is involved in the manufacturing of generic drugs in various form

  • No Image
    Synchron Research Services Pvt Ltd

    Synchron was started by a group of pharmaceutical professionals in 1998. Today Synchron is a leading Contract Research Organization in India providing broad range of clinical re

  • No Image
    Synergy Remedies Pvt Ltd

    Synergy Remedies Pvt Ltd is an Active Pharma Ingredient ( API) manufacturing unit coming up with state of art technology and as per the standards of GMP and WHOGMP etc. The capa